Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence will support the venture with $10 million in equity financing and drug development expertise.
Today the Longevity Research Institute, a non-profit organization that designs and funds animal studies to validate the anti-aging effects of promising compounds, announced the initiation of its first lifespan study, which will be conducted at Ichor Therapeutics.
Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally and internationally. Most notably, he has been involved in the development of Remicade® (the first anti-TNF biological drug) and in a very large number of clinical trials, Phase I to IV, bringing innovative first-in-class drugs to market.
Ship of Theseus, LLC, a bioengineering company that focuses on stem cell therapies for aging and age-associated disease, announces the initiation of a murine lifespan study to be conducted at Ichor Therapeutics, Inc. This work will inform new targets for therapeutic intervention in aging.
A landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.
The State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration program.
The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.
Each year Syracuse’s economic development counsel and chamber of commerce, CenterState CEO, recognizes Central New York businesses for their outstanding achievements during the past year. Ichor Therapeutics, Inc. has been selected as a finalist for 2018.
Kelsey Moody was a medical student at Upstate Medical University when he landed a $540,000 research grant and set up his own pharmaceutical research company.
Aaron Wolfe expects to finish up his Ph.D. in physics this semester. He has been working on his doctorate since 2011 and should have been done by now, he says, but a few things have gotten in the way—like helping to run a company, Ichor Therapeutics, of which he is chief operating officer.